X

Trial Profile

Observational biomarker study related to the resistance mechanism of 3rd generation EGFR-TKI (osimertinib)(LOGIK1607)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Biomarker; Pharmacodynamics
Acronyms LOGIK1607

Most Recent Events

10 Jul 2021 Status changed from active, no longer recruiting to completed.
30 Oct 2019 Status changed to active, no longer recruiting as per results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
30 Oct 2019 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com